As the newest generation of calcimimetic, cinacalcet was proven to be effective in patients with inoperable parathyroid cancer by increasing the affinity of calcium-sensing receptors and reducing the secretion of parathyroid hormone (12). This evidence concerns the gene PTH and malignant tumor of parathyroid gland.